Skip to main content
SpringerLink
Log in

Experience with daptomycin daily dosing in ICU patients undergoing continuous renal replacement therapy

  • Brief Report
  • Published:
Infection Aims and scope Submit manuscript

Abstract

Purpose

For critically ill patients undergoing continuous renal replacement therapy (CRRT), daptomycin dosing recommendations are scarce. We, therefore, retrospectively assessed routinely measured daptomycin plasma concentrations, daptomycin dose administered and microbiological data in 11 critically ill patients with Gram-positive infections that had received daptomycin once daily.

Methods

The retrospective analysis included critically ill patients treated at the intensive care unit (ICU) who had daptomycin plasma concentrations measured.

Results

Daptomycin dose ranged from 3 to 8 mg/kg/q24 h in patients undergoing CRRT (n = 7) and 6 to 10 mg/kg/q24 h in patients without CRRT (n = 4). Peak and trough concentrations showed a high intra- and inter-patient variability in both groups, independent of the dosage per kg body weight. No drug accumulation was detected in CRRT patients with once-daily daptomycin dosing. Causative pathogens were Enterococcus faecium (n = 6), coagulase-negative Staphylococcus (n = 2), Staphylococcus aureus (n = 2) and unknown in one patient. Microbiological eradication was successful in 8 of 11 patients. Two of three patients with unsuccessful microbiological eradication and fatal outcome had an Enterococcus faecium infection.

Conclusion

In critically ill patients undergoing CRRT, daptomycin exposure with once-daily dosing was similar to ICU patients with normal renal function, but lower compared to healthy volunteers. Our data suggest that daptomycin once-daily dosing is appropriate in patients undergoing CRRT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 1995;273:117–23.

    Article  PubMed  CAS  Google Scholar 

  2. Rether C, Conen A, Grossenbacher M, Albrich WC. A rare cause of pulmonary infiltrates one should be aware of: a case of daptomycin-induced acute eosinophilic pneumonia. Infection. 2011;39:583–5.

    Article  PubMed  CAS  Google Scholar 

  3. CUBICIN® Product information. 2010.

  4. van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient—a review of the literature. Eur J Clin Microbiol Infect Dis. 2011;30:603–10.

    Article  PubMed  Google Scholar 

  5. Kirby A, Edwards C, Broughton CM, Williams NJ. Glycopeptide and daptomycin resistance in community-associated MRSA in the UK. Infection. 2011;39:277–9.

    Article  PubMed  CAS  Google Scholar 

  6. Lewis JS 2nd, Owens A, Cadena J, Sabol K, Patterson JE, Jorgensen JH. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother. 2005;49:1664–5.

    Article  PubMed  Google Scholar 

  7. Munoz-Price LS, Lolans K, Quinn JP. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis. 2005;41:565–6.

    Article  PubMed  Google Scholar 

  8. Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis. 2009;9:617–24.

    Article  PubMed  CAS  Google Scholar 

  9. Kelesidis T, Humphries R, Uslan DZ, Pegues DA. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis. 2011;52:228–34.

    Article  PubMed  Google Scholar 

  10. Antachopoulos C, Iosifidis E, Sarafidis K, et al. Serum levels of daptomycin in pediatric patients. Infection. 2012. [Epub ahead of print].

  11. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294:813–8.

    Article  PubMed  CAS  Google Scholar 

  12. Churchwell MD, Pasko DA, Mueller BA. Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif. 2006;24:548–54.

    Article  PubMed  CAS  Google Scholar 

  13. Vilay AM, Grio M, Depestel DD, et al. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit Care Med. 2011;39:19–25.

    Article  PubMed  CAS  Google Scholar 

  14. Rudiger A, Rentsch K, Maggiorini M, Corti N. Daptomycin pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. Crit Care Med. 2011;39:1243–4; author reply 1244–5.

    Article  PubMed  Google Scholar 

  15. Khadzhynov D, Slowinski T, Lieker I, et al. Plasma pharmacokinetics of daptomycin in critically ill patients with renal failure and undergoing CVVHD. Int J Clin Pharmacol Ther. 2011;49:656–65.

    PubMed  CAS  Google Scholar 

  16. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003;47:1318–23.

    Article  PubMed  CAS  Google Scholar 

  17. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006;50:3245–9.

    Article  PubMed  CAS  Google Scholar 

  18. Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2004;48:2799–807.

    Article  PubMed  CAS  Google Scholar 

  19. Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48:63–8.

    Article  PubMed  CAS  Google Scholar 

  20. European Committee on Antimicrobial Susceptibility Testing. http://www.eucast.org. 2006.

  21. Cha R, Grucz RG Jr, Rybak MJ. Daptomycin dose–effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother. 2003;47:1598–603.

    Article  PubMed  CAS  Google Scholar 

  22. Hall AD, Steed ME, Arias CA, Murray BE, Rybak MJ. Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2012;56:3174–80.

    Article  PubMed  CAS  Google Scholar 

  23. Gallagher JC, Perez ME, Marino EA, LoCastro LG, Abrardo LA, MacDougall C. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients. Pharmacotherapy. 2009;29:792–9.

    Article  PubMed  CAS  Google Scholar 

  24. Kullar R, Davis SL, Levine DP, et al. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy. 2011;31:527–36.

    Article  PubMed  CAS  Google Scholar 

  25. Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis. 2009;49:177–80.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

Dr. Corti was on the advisory board for Novartis, Basel, Switzerland. Drs. Preiswerk, Rudiger and Fehr have not disclosed any potential conflicts of interest.

Author information

Authors and Affiliations

  1. Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, Raemistrasse 100, 8091, Zurich, Switzerland

    B. Preiswerk & J. Fehr

  2. Institute of Anaesthesiology, University Hospital of Zurich, Raemistrasse 100, 8091, Zurich, Switzerland

    A. Rudiger

  3. Department of Clinical Pharmacology and Toxicology, University Hospital of Zurich, Raemistrasse 100, 8091, Zurich, Switzerland

    N. Corti

Authors
  1. B. Preiswerk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Rudiger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Fehr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Corti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Corti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Preiswerk, B., Rudiger, A., Fehr, J. et al. Experience with daptomycin daily dosing in ICU patients undergoing continuous renal replacement therapy. Infection 41, 553–557 (2013). https://doi.org/10.1007/s15010-012-0300-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-012-0300-3

Keywords

Search

Navigation